Last reviewed · How we verify
Pathogen-Reduced Plasma
Pathogen-reduced plasma is human blood plasma treated with a pathogen reduction technology to inactivate or remove infectious agents while preserving hemostatic function.
Pathogen-reduced plasma is human blood plasma treated with a pathogen reduction technology to inactivate or remove infectious agents while preserving hemostatic function. Used for Coagulation factor replacement in patients requiring plasma transfusion, Volume expansion and hemostatic support in acute bleeding or surgical settings.
At a glance
| Generic name | Pathogen-Reduced Plasma |
|---|---|
| Also known as | PRP |
| Sponsor | Coalition for National Trauma Research |
| Drug class | Blood product / Plasma derivative |
| Modality | Small molecule |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | FDA-approved |
Mechanism of action
The product uses solvent/detergent or photochemical treatment methods to inactivate enveloped and non-enveloped viruses, bacteria, and other pathogens present in donated plasma. This reduces transfusion-transmitted infection risk while maintaining the coagulation factors and other plasma proteins needed for hemostasis and volume replacement.
Approved indications
- Coagulation factor replacement in patients requiring plasma transfusion
- Volume expansion and hemostatic support in acute bleeding or surgical settings
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Fever
- Circulatory overload
Key clinical trials
- Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis (NA)
- Fibrinogen in Liver Transplant (PHASE4)
- Fibrinogen in Liver Transplant Subjects (PHASE4)
- Plasma Resuscitation Without Lung Injury (PHASE4)
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients (PHASE2)
- Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort (PHASE2)
- Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults (PHASE3)
- Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pathogen-Reduced Plasma CI brief — competitive landscape report
- Pathogen-Reduced Plasma updates RSS · CI watch RSS
- Coalition for National Trauma Research portfolio CI